DDInter1397 DDInter1387
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market.
Paroxetine {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Panobinostat
Paroxetine {u} (Compound) downregulates {v} (Gene) RPS4Y1
RPS4Y1 {u} (Gene) is downregulated by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Panobinostat
Paroxetine {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Nifedipine
Nifedipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Panobinostat
Paroxetine {u} (Compound) downregulates {v} (Gene) RPS4Y1
RPS4Y1 {u} (Gene) is downregulated by {v} (Compound) Nifedipine
Nifedipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Panobinostat
Paroxetine {u} (Compound) causes {v} (Side Effect) Purpura
Purpura {u} (Side Effect) is caused by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Panobinostat
Paroxetine {u} (Compound) causes {v} (Side Effect) Purpura
Purpura {u} (Side Effect) is caused by {v} (Compound) Nifedipine
Nifedipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Panobinostat
Paroxetine {u} (Compound) downregulates {v} (Gene) PCNA
PCNA {u} (Gene) is downregulated by {v} (Compound) Dabrafenib
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Panobinostat
Paroxetine {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Dabrafenib
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Panobinostat
Paroxetine {u} (Compound) downregulates {v} (Gene) PCNA
PCNA {u} (Gene) is downregulated by {v} (Compound) Diflunisal
Diflunisal {u} may lead to a major life threatening interaction when taken with {v} Panobinostat
Paroxetine {u} (Compound) causes {v} (Side Effect) Vomiting
Vomiting {u} (Side Effect) is caused by {v} (Compound) Nepafenac
Nepafenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Panobinostat
Paroxetine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Paroxetine (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Paroxetine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Paroxetine (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Paroxetine (Compound) causes Purpura (Side Effect) and Purpura (Side Effect) is caused by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Paroxetine (Compound) causes Purpura (Side Effect) and Purpura (Side Effect) is caused by Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Paroxetine (Compound) downregulates PCNA (Gene) and PCNA (Gene) is downregulated by Dabrafenib (Compound) and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Paroxetine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Dabrafenib (Compound) and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Paroxetine (Compound) downregulates PCNA (Gene) and PCNA (Gene) is downregulated by Diflunisal (Compound) and Diflunisal may lead to a major life threatening interaction when taken with Panobinostat
Paroxetine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Nepafenac (Compound) and Nepafenac may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat